Association of Primary Immunodeficiencies in Parents With Psychiatric Disorders and Suicidal Behavior in Their Offspring.
Journal
JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
pmc-release:
01
02
2024
medline:
7
4
2023
pubmed:
2
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
Maternal immune activation (MIA) leading to altered neurodevelopment in utero is a hypothesized risk factor for psychiatric outcomes in offspring. Primary antibody immunodeficiencies (PIDs) constitute a unique natural experiment to test the MIA hypothesis of mental disorders. To assess the association of maternal and paternal PIDs with psychiatric disorders and suicidal behavior in offspring. Cohort study of 4 294 169 offspring of parents with and without PIDs living in Sweden at any time between 1973 and 2013. Data were extracted from Swedish nationwide health and administrative registers and were analyzed from May 5 to September 30, 2022. All individuals with diagnoses of PIDs identified between 1973 and 2013 from the National Patient Register were included. Offspring were included if born before 2003. Parent-offspring pairs in which both parents had a history of PIDs were excluded. Lifetime records of parental PIDs according to the International Classification of Diseases, Eighth Revision (ICD-8); International Classification of Diseases, Ninth Revision (ICD-9); and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnostic codes. Lifetime records of 10 psychiatric disorders and suicidal behavior identified using ICD-8, ICD-9, and ICD-10 diagnostic codes, including suicide attempts and death by suicide, among offspring. Covariates included sex, birth year, parental psychopathology, suicide attempts, and autoimmune diseases. Additional analyses excluded offspring with their own PIDs and autoimmune diseases. Poisson regression models were fitted separately for mothers and fathers to estimate incidence rate ratios (IRRs) and 95% CIs for the risk of psychiatric and suicidal behavior outcomes in the offspring of PID-exposed vs PID-unexposed mothers or fathers. The cohort included 4 294 169 offspring (2 207 651 males [51.4%]) and 3 954 937 parents (1 987 972 females [50.3%]). A total of 7270 offspring (0.17%) had parents with PIDs, and 4 286 899 offspring had parents without PIDs. In fully adjusted models, offspring of mothers with PIDs had an increased risk of any psychiatric disorder, while no such risks were observed in offspring of fathers with PIDs (IRR, 1.17; 95% CI, 1.10-1.25 vs IRR, 1.03; 95% CI, 0.94-1.14; P < .001). Likewise, an increased risk of suicidal behavior was observed among offspring of mothers with PIDs but not offspring of fathers with PIDs (IRR, 1.20; 95% CI, 1.06-1.36 vs IRR, 1.10; 95% CI, 0.91-1.34; P = .01). For the offspring of mothers with PIDs, the risk of developing any psychiatric disorder was significantly higher for those with mothers with 6 of 10 individual disorders, with IRRs ranging from 1.15 (95% CI, 1.04-1.26) for anxiety and stress-related disorders and 1.15 (95% CI, 1.03-1.30) for substance use disorders to 1.71 (95% CI, 1.37-2.14) for bipolar disorders. Offspring of mothers with both PIDs and autoimmune diseases had the highest risk for any psychiatric disorder (IRR, 1.24; 95% CI, 1.11-1.38) and suicidal behavior (IRR, 1.44; 95% CI, 1.17-1.78). Findings of this cohort study suggest that maternal, but not paternal, PIDs were associated with a statistically significant increased risk of psychiatric disorders and suicidal behavior in the offspring, particularly when PIDs co-occur with autoimmune diseases. These findings align with the MIA hypothesis of mental disorders, but the precise mechanisms remain to be elucidated.
Identifiants
pubmed: 36723922
pii: 2801117
doi: 10.1001/jamapsychiatry.2022.4786
pmc: PMC10077106
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-330Références
JAMA Psychiatry. 2016 Nov 01;73(11):1135-1144
pubmed: 27706475
Nat Rev Neurol. 2021 Sep;17(9):564-579
pubmed: 34341569
Methods Mol Biol. 2011;675:215-20
pubmed: 20949391
JAMA Psychiatry. 2020 Nov 1;77(11):1147-1154
pubmed: 32520326
J Autoimmun. 2019 May;99:52-72
pubmed: 30795880
Psychiatry Res. 2019 Jan;271:23-30
pubmed: 30458317
JAMA Netw Open. 2022 Apr 1;5(4):e227503
pubmed: 35426923
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
Transl Psychiatry. 2022 Mar 18;12(1):112
pubmed: 35304436
J Allergy Clin Immunol. 2002 Apr;109(4):581-91
pubmed: 11941303
Behav Brain Res. 2016 Jan 1;296:61-69
pubmed: 26327239
Mol Psychiatry. 2018 Jul;23(7):1652-1658
pubmed: 29133949
Eur J Epidemiol. 2019 Mar;34(3):211-219
pubmed: 30840181
Schizophr Bull. 2016 Jan;42(1):125-33
pubmed: 26303935
Eur J Epidemiol. 2009;24(11):659-67
pubmed: 19504049
JAMA. 2018 Jun 19;319(23):2388-2400
pubmed: 29922828
Transl Psychiatry. 2021 Jan 21;11(1):71
pubmed: 33479207
J Am Acad Child Adolesc Psychiatry. 2022 Sep;61(9):1155-1167
pubmed: 35367322
Biol Psychiatry. 2022 Jul 18;:
pubmed: 36155699
Lancet Psychiatry. 2022 Oct;9(10):782-791
pubmed: 36087610
J Affect Disord. 2016 Mar 15;193:165-74
pubmed: 26773919
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1929-1957.e5
pubmed: 30797077
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Mol Psychiatry. 2018 May;23(5):1189-1197
pubmed: 28348386
Lancet Psychiatry. 2019 Jun;6(6):477-492
pubmed: 31029623
Asian J Psychiatr. 2022 Feb;68:102972
pubmed: 34954611
Neuropsychopharmacology. 2017 Jan;42(1):271-283
pubmed: 27377015
J Child Psychol Psychiatry. 2019 Jul;60(7):803-812
pubmed: 30178543
J Clin Med. 2020 Aug 07;9(8):
pubmed: 32784803
Am J Psychiatry. 2010 Mar;167(3):261-80
pubmed: 20123911
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Pediatrics. 2012 Jan;129(1):e232-46
pubmed: 22201156
Curr Top Behav Neurosci. 2020;44:35-47
pubmed: 30852763
Mol Psychiatry. 2018 Apr;23(4):1001-1013
pubmed: 28322282
JAMA Psychiatry. 2019 Jun 1;76(6):594-602
pubmed: 30840048
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791